Journals / Anadolu Kardiyoloji Dergisi / 2004 / Cilt: 4 - Sayı: 1

Femoral vascular complications after percutaneus coronary interventions

Perkütan koroner girişimler sonrası femoral vasküler komplikasyonlar

Pages
39–44
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The age, gender, glycoprotein 2b/3a use, thrombolytic use, intraaortic balloon treatment, transient pacemaker treatment, reintervention history, hypertension, diabetes mellitus, smoking status, family history and the correlations of these parameters with local vascular complications were assessed in all patients.Results: Pseudoaneurysm incidence was significantly correlated with; age [(n=13 68.0%) p=0.0001, OR 8.38], female gender [(n=12 63.1%) p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to investigate peripheral vascular complications and their relation with treatment and clinical parameters in percutaneous transluminal coronary angioplasty (PTCA) patients.
📊
Key Findings & Data:Methods: We included 321 patients (aged 57±11 years) underwent PTCA between November 2001-August 2002.
💡
Conclusion & Impact:The age, gender, glycoprotein 2b/3a use, thrombolytic use, intraaortic balloon treatment, transient pacemaker treatment, reintervention history, hypertension, diabetes mellitus, smoking status, family history and the correlations of these parameters with local vascular complications were assessed in all patients.Results: Pseudoaneurysm incidence was significantly correlated with; age [(n=13 68.0%) p=0.0001, OR 8.38], female gender [(n=12 63.1%) p
🔬Design:Research Article
📍Scope:2001 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to investigate peripheral vascular complications and their relation with treatment and clinical parameters in percutaneous transluminal coronary angioplasty (PTCA) patients. Methods: We included 321 patients (aged 57±11 years) underwent PTCA between November 2001-August 2002. The age, gender, glycoprotein 2b/3a use, thrombolytic use, intraaortic balloon treatment, transient pacemaker treatment, reintervention history, hypertension, diabetes mellitus, smoking status, family history and the correlations of these parameters with local vascular complications were assessed in all patients.Results: Pseudoaneurysm incidence was significantly correlated with; age [(n=13 68.0%) p=0.0001, OR 8.38], female gender [(n=12 63.1%) p

Özet

Amaç: Perkütan translüminal koroner anjiyoplasti (PTKA) uygulanan hastalarda, periferik vasküler komplikasyonlarla, klinik parametreler ve tedaviler arasındaki ilişkiyi araştırdık. Yöntemler: Çalışmaya, Kasım 2001-Ağustos 2002 arasında PTKA uygulanan, ortalama yaşları 57±11 yıl olan 321 hasta alındı. Hastalar; yaş, cinsiyet, glikoprotein 2b/3a, trombolitik ajan, intraaortik balon pompası kullanımı, geçici pacemaker uygulanması, önceden aynı bölgeden PTKA uygulanmış olması, hipertansiyon, diyabetes mellitus, sigara, aile öyküsü ve bunların lokal vasküler komplikasyonlarla ilişkisi açısından incelendi.Bulgular: Majör periferik komplikasyonlardan olan psödoanevrizma gelişimi ile; yaş [(n=13 %68) p=0.0001, OR 8.38], kadın cinsiyeti [(n=12 %63.1) p

🔖

Cite This Article

DÖVEN, O., ÇAMSARI, A., ÇİÇEK, D., AKKUŞ, N., CİN, V. G., KATIRCIBAŞI, M. T., ÖZCAN, İ. T., PEKDEMİR, H. (2022). Femoral vascular complications after percutaneus coronary interventions. Anadolu Kardiyoloji Dergisi, Cilt: 4 - Sayı: 1, 39–44. https://ajindex.com/articles/437486

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Blankensip JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ Califf RM, for the EPIC investigators. Vascular access site complications after percutaneous coronary intervention with abciximab in the evalatuion of C7E3 for the prevention of ischemic complications (EPIC) trial. Am J Cardiol 1998;81:36-40
  2. Waskman R, King SB, Douglas JS, et al. Predictors of groin complications after balloon and new device coronary intervention. Am J Cardiol 1995;75:886-9
  3. Skillman JJ, Kim D, Baim DS. Vascular complications of percutaneous femoral cardiac interventions. Arch Surg 1988; 123:1207-12
  4. Roberts SR, Main D, Pinkerton J. Surgical therapy of femoral artery pseudoaneurysm after angiography. Am J Surg 1987; 154:676-80
  5. McMillan I, Murie JA. Vascular injury following cardiac catheterization. Br J Surg 1984;71:832-5
  6. Babu SC, Piccorelli GO, Stah PM, Stein JH, Clauss RH. Incidence and results of arterial complications among 16350 patients undergoing cardiac catheterization. J Vasc Surg 1989;10:113-6
  7. Hessel SJ, Adams DF, Abrams HL. Complications of angiography. Diagn Radiol 1981;138: 273-81
  8. Seidenberg B, Hurwitt ES. Retrograde femoral (Seldinger) aortography: surgical complications in 26 cases. Ann Surg 1966;163:221-6
  9. Bourrassa MG, Nobel J. Complication rate of coronary arteriography:a review of 5250 cases studied by a percutaneous femoral technique. Circulation 1976;53:106-14
  10. Altin RS, Flicker S, Naidech HJ. Pseudoaneurysm and arteriovenosus fistula after femoral artery catheterization: association with low femoral punctures. Am J Radiol 1989; 152: 629-31
  11. Izumi AK, Samlaska CP, Denise WL, Bruno WP. Septic embolization arising from pseudoaneurysms following percutaneous transluminal coronary angioplasty: a report of 2 cases and review of the literature. Cutis 2000;6:447-52
  12. Alhan C, Tuygun A.K, Alhan S ve ark. Kardiyak kateterizasyona bağlı periferik vasküler komplikasyonların tanısında renkli Doppler sonografinin yeri. Haydarpaşa Kardiyoloji ve Kardiyo-Vasküler Cerrahi Bülteni 1996; 4: 27-31
  13. Frederic S, Resnic MS, Blake GJ, et al. Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein 2b/3a inhibitors. Am J Cardiol 2001;88:493-6
  14. Chamberlin JR, Lardi AB, McKeever LS, et al. Use of vascular sealing devices (Vassoseal and Perclose) versus assisted manual compression (femstop) in transcatheter coronary interventions requiring abciximab. Cath